Kelly Dooley, MD, PhD

Faculty

Titles:

Assistant Professor, Medicine and Pharmacology and Molecular Sciences

Email:

kdooley1@jhmi.edu

SciVal:

SciVal Link

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Categories

Events

«

November 2017

»
S
M
T
W
T
F
S
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·

Projects

Evaluating an automated system for...

We are evaluating the accuracy and cost-effectiveness of TBDx, an automated digital microscopy system, as a screening test to...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

A Blueprint for Success: Understanding the...

We are using a combination of statistical analysis and transmission modeling, in collaboration with the NYC Dept of Health &...

Read More

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More